# SHINING A LIGHT ON THE...... Baillie Gifford WW Health Innovation Fund

#### **AT A GLANCE**

#### **Investment Objective**

The investment objective of the Fund is to provide strong returns over the long term by investing primarily in a global equity portfolio selected from companies engaged in the health care industry. The Fund may also invest in other transferable securities, money market instruments, cash and cash equivalents.

Inception Date	15 December 2020	
Fund Factsheet Link	https://www.morningstar.co.uk/uk/funds/snapsh	
	ot/snapshot.aspx?id=0P000107J2	

Management	
Manager Name	Start Date
Julia Angeles	15 December 2020
Marina Record	15 December 2020
Rose Nguyen	15 December 2020

#### **FUND PERFORMANCE**

Performance from 1<sup>st</sup> January 2021 – 31<sup>st</sup> January 2022:

	2021	2022
Baillie Gifford WW Health Innovation Fund	-7.21%	-24.35%
MSCI ACWI NR USD	19.63%	-4.00%

#### Performance since launch:

	Since launch
Baillie Gifford WW Health Innovation Fund	-28.96%
MSCI ACWI NR USD	15.05%

You should note that past performance is not a reliable indicator of future returns and the value of your investments can fall as well as rise. The total return reflects performance without sales charges or the effects of taxation but is adjusted to reflect all on-going fund expenses and assumes reinvestment of dividends and capital gains. If adjusted for sales charges and the effects of taxation, the performance quoted would be reduced.

Tracking Error	Active Share	Upside Capture Ratio	Downside Capture Ratio	Batting Average	Beta	Alpha	Equity Style
-	-	-	-	-	-	1	Growth / Mid

## LWM Consultants Ltd

Volatility Measurements	
3-Yr Std Dev (volatility) -	
3-Yr Mean Return (average)	-

Investment Style Details		
Giant	8.30%	
Large	33.24%	
Medium	37.05%	
Small	15.92%	
Micro	4.29%	

Top 5 Holdings – 40 Equity Holdings		
Moderna Inc	Healthcare	8.79%
Sartorius AG Participating Prefe	Healthcare	5.67%
10x Genomics Inc Ordinary Shares	Healthcare	5.53%
M3 inc	Healthcare	5.32%
Illumina Inc	Healthcare	4.60%

Top 5 Regions		
United States	70.07%	
Europe ex Euro	12.06%	
Eurozone	5.74%	
Asia – Emerging	5.72%	
Japan	5.38%	

#### UPDATE....

This is a new strategy but leans into the wider Baillie Gifford Group and aims to take advantage of the positive impact of biology to health and the health care industry. They see that the changes happening are a biological revolution that push our understanding of biology, with sequencing the genome being the principal driver behind this.

The pace of change is getting faster every day and they want to invest in companies that are transforming the healthcare industry. They invest across five buckets: understanding of diseases, diagnostics, treatment, prevention, and operational efficiency.

They are looking at a 5-year holding period and allowing winners to run. The team is eight strong with three lead managers. In turn the team have access to leading scientists through leaders and writers, entrepreneurs, and public and private companies, as well as capital funds.

Some examples of stocks include 10x Genomics, which is increasing the resolution of sequencing with the ability to compare the genome of a healthy cell vs a diseased cell. This is crucial to the next phase of the biological revolution.

Looking long term means that short term volatility opens opportunities. Teledoc has returned to prepandemic price levels which has enabled them to add to the position.

### LWM Consultants Ltd

Another example is Moderna who they engaged with for two years before they came to market. This is seen by many as COVID stock, but it is already thinking about different diseases they can expand into. It reflects the disconnect between what the market thinks and what is actually happening.

In summary, this strategy only invests in listed companies but they do research into the unlisted space and so are aware of companies before they come to market. Although the market volatility has impacted the performance of the strategy, they believe this is providing them with opportunities to add to current positions. As an alternative global strategy with long term growth potential, this offers an interesting option, and one we have added to our watchlist.

As a takeaway, the team want investors to see impact as critical to what they do – this is seen as the impact the companies they invest in can bring to the world, and the impact that Baillie Gifford can have on these companies.

The source of information in this note has been provided by Baillie Gifford and is correct as of January 2022. These are notes from meeting the fund manager or representative and should not be seen as a recommendation to purchase any fund mentioned. Any reference to shares is not a recommendation to buy or sell. Should you wish to decide based on these notes we cannot take responsibility for this, and you should carry out your own research before making a decision. We would also recommend that you receive advice before following up on any decision.